
Valneva SE (NASDAQ:VALN) is trading significantly higher Wednesday following results from an initial laboratory study, which demonstrated that serum antibodies induced by three doses of Valneva's COVID-19 vaccine candidate, VLA2001, neutralize the omicron variant.
Samples from 30 participants in the Phase 1/2 trial of Valneva's COVID-19 candidate were used in a pseudovirus assay to analyze neutralization of the ancestral SARS-CoV-2 virus as well as the delta and omicron variants.